AmerisourceBergen’s Update on the Distribution of Donated Remdesivir from Gilead Sciences, released May 5, 2020, provides the following information:

On May 1, 2020, the FDA granted an Emergency Use Authorization (EUA) for Gilead’s remdesivir for the treatment of COVID-19.  Gilead has been working closely with the U.S. government on preparations to donate and distribute remdesivir across the country to treat critical COVID-19 patients, and will work with AmerisourceBergen as the sole distributor for the donated remdesivir.

Given the severity of illness of patients appropriate for remdesivir treatment and the limited availability of drug supply, hospitals with intensive care units and other hospitals that the U.S. government deems most in need will receive priority in the distribution of donated remdesivir. The U.S. government will coordinate the distribution of remdesivir to hospitals in regions most heavily impacted by COVID-19. Neither Gilead nor AmerisourceBergen are deciding which hospitals will receive remdesivir.

If you are a hospital identified by the U.S. government as a recipient for donated remdesivir, you will be proactively contacted by an AmerisourceBergen representative. Retail and specialty pharmacies are not eligible to receive donated remdesivir.

• For questions about the distribution of remdesivir, call the national remdesivir donation inquiry line at 877-987-4987. 
• To find out if your hospital has been designated to receive donated remdesivir, you can email remdesivir@amerisourcebergen.com and provide your facility name, ship to address with zip code, your Health Industry Number and your DEA number. 
• For information on clinical trials that are testing the use of remdesivir in COVID-19, please visit  www.clinicaltrials.gov.
• For additional medical information about remdesivir, please visit  www.askgileadmedical.com/remdesivir/ or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.

We will update this message as additional information becomes available.

Source: https://www.amerisourcebergen.com/coronavirus-covid-19-information